Pharma Innovation vs. Patient Access: Why New Drugs Take Time to Reach India

India is celebrated as the “pharmacy of the world” for making affordable medicines available globally. However, many Indian patients face long waits for the latest life-saving drugs. There is a growing debate around Pharma innovation vs patient access India, as many wonder why cutting-edge medicines take so long to reach Indian markets. 

This blog explains the key reasons, regulatory processes, and challenges behind this delay in a clear and easy-to-understand way.

 

What Is Drug Lag in India?

The term drug lag in India refers to the delay between when a drug gets approved globally and when it becomes available for Indian patients. A drug available in the US or Europe could take several years before patients in India can access it.

The primary reasons for this lag include regulatory hurdles, the high costs of local trials, and strict patent laws.

A study published in PMC on new cardiovascular drugs found that 56 out of 75 (74.66%) were approved in India during the period from 1999 to 2011, indicating a significant delay compared to the US and EU. This becomes especially critical in life-threatening illnesses like cancer, where timely access can significantly improve survival outcomes.

New Drug Approval Process Work in India?

The new drug approval process India is one of the longest hurdles a new medicine faces. It’s designed to ensure safety but is often criticized for being slow and complex.

Here’s how the process works:

Stage	What Happens	Time Taken
Clinical Trial Application	Pharma companies apply to conduct human trials	6–12 months
CDSCO Data Evaluation	Experts at the Central Drugs Standard Control Organization (CDSCO) evaluate the trial results	6–9 months
Final DGCI Approval	The Drugs Controller General of India (DGCI) gives the final go-ahead for the drug to be sold in India	12–24 months

Even if a drug is approved globally, Indian regulators often require local clinical trials, delaying patient access further. The CDSCO approval process and DGCI approval timeline add considerable time before patients can benefit from innovative treatments.

A research published in the International Journal of Basic & Clinical Pharmacology compares the drug approval processes and timelines across different countries, including India.

 

Biggest Challenges of New Drugs in India

The challenges of new drugs in India are multi-faceted and often discourage innovators.

Here are the top challenges:

• Heavy regulatory burden slowing approvals

• High costs of clinical trials and local testing

• Patent-related complications under pharmaceutical patent laws India

• Strict price caps enforced by the Drug Price Control Order India and NPPA price control drugs
  
  

Because of these issues, many companies hesitate to introduce new drugs in India.

For example, a breast cancer pateint may have to wait several years to access a new drug already available abroad, simply because of the time-consuming processes in place.

As per CDSCO data of August 2025, the Central Drugs Standard Control Organisation (CDSCO) has approved 20 new drugs in India

New Drugs and Clinical Trials Rules 2019 Affect Access in 2025 

The new drugs and clinical trials rules 2019 were introduced by the Indian government to bring more transparency, safety, and efficiency into the process of getting new medicines approved. These rules aimed to streamline the system but, in practice, they have delivered mixed results.

What’s Improved in 2025:

• Clearer and stricter patient consent processes help protect patient rights.

• Faster adverse event reporting ensures any side effects are quickly flagged and addressed.

• Ethics committees now follow standardized timelines and stricter guidelines, reducing subjectivity in decision-making.
  
  

Still Holding Back Progress:

• Despite improvements, many companies still struggle with ambiguous documentation demands.

• Ethics committees take longer than expected to approve trial protocols due to lack of resources in some regions.

• The requirement for local bridging trials remains common, even when global data is robust.

This situation deepens the debate on Pharma innovation vs patient access India. On one hand, India is trying to maintain high safety standards. On the other, patients are left waiting for years to get new treatment options, even in cases where they are critically needed, such as novel cancer therapies or advanced heart disease drugs.

As per Indian Express the Indian government has proposed amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, aiming to reduce regulatory delays and approval timelines. 

 

Access to New Anti-Cancer and Orphan Drugs Limited in India

Access to new anti-cancer drugs in India is particularly challenging due to affordability and regulatory hurdles.

The cost of cancer treatment in India ranges from ₹5 lakh to ₹50 lakh per year, and high-cost innovative drugs add further strain.

Orphan drugs (used for rare diseases) face greater difficulties because:

• Small market size

• High development and distribution costs

• Limited industry interest despite the orphan drugs policy India designed to encourage rare disease treatments
  
  

Even after regulatory approval, drug import regulations India make it hard for hospitals to stock these medicines promptly.

Some patient assistance program India initiatives offer medicines at reduced or no cost to patients, but many are still unaware of these schemes.

 

Key Regulatory Barriers to New Drug Availability

A major reason why new drugs are not available in India is the long and complicated approval system.

Key barriers include:

• Local clinical trials are still mandatory even when global trials exist

• Slow CDSCO approval process

• Prolonged DGCI approval timeline

• Patent laws that focus on generics rather than innovation

• Price control policies like Drug Price Control Order India limiting industry profitability
  
  

For instance, a novel cardiac drug may receive global approval but take 2–3 years for DGCI approval in India because of additional local trials and paperwork.

 

FAQs 

Q1: What causes drug lag in India?
Drug lag in India happens due to long approval processes, high trial costs, and strict patent laws.

Q2: Why do new drugs take so long to reach India?
New drugs take time because of the complex new drug approval process India, mandatory local trials, and long CDSCO approval process and DGCI approval timeline.

Q3: What is the CDSCO approval process?
It involves clinical trial approvals, data evaluation by CDSCO experts, and final DGCI clearance.

Q4: How long does DGCI approval take in India?
Typically between 12–24 months depending on the drug’s complexity and trial data.

Q5: What are the challenges of new drugs in India?
They include costly trials, patent restrictions, Drug Price Control Order India, and NPPA price control drugs.

Q6: How does the Drug Price Control Order affect new medicines?
It caps prices of essential drugs, discouraging companies from introducing expensive innovative medicines.

Q7: What is the orphan drugs policy in India?
It supports development of medicines for rare diseases but remains underutilized due to India pharmaceutical market size and cost.

Q8: How do patient assistance programs work in India?
They help patients get expensive medicines at low or no cost by working directly with pharma companies or NGOs.

 

Wrapping Up

India’s pharmaceutical industry is slowly evolving toward innovation, but the journey is far from over. Stronger policies, better industry-government collaboration, and wider awareness of patient assistance program India can help balance the ongoing debate between Pharma innovation vs patient access India. For now, patients continue to face long waits and high costs, particularly in cancer and rare disease treatments.

Read Also

1. India’s Pharma Industry Urges Tax Relief to Drive Innovation

2. Are Biosimilars as Effective as Original Drugs?

 

References

1. Konwar M, Maurya MR, Nishandar TB, Thatte UM, Gogtay NJ. An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018). Perspect Clin Res. 2021;12(3):159-164. doi:10.4103/picr.PICR_99_19

2. Balganesh T, Kundu TK, Chakraborty TK, Roy S. Drug discovery research in India: current state and future prospects. ACS Med Chem Lett. 2014;5(7):724-726. Published 2014 May 23. doi:10.1021/ml500183c

3. https://www.pharmaceutical-technology.com/pricing-and-market-access/india-issues-new-clinical-trial-rules-expedite-new-drug-html/

 

Disclaimer: The content in this blog is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your doctor or a registered dietitian before making any changes to your diet, especially if you have a medical condition or are taking prescribed medication. While the information is based on trusted sources, individual needs and results may vary. MrMed does not promote or endorse any specific food or treatment mentioned unless explicitly stated.